ICP
BIO icon

Inclusive Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Inclusive Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-60,000
Closed -$21.5M – 5
2023
Q3 		$21.5M Buy
+60,000
New +$23.1M 2.13% 8

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Inclusive Capital Partners's BIO Position: Q4 2023 in Review

Inclusive Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 60,000 shares — an estimated $21.5M sold.

Inclusive Capital Partners first reported a position in BIO in Q3 2023 and held it in 1 quarter. The position peaked at $21.5M in Q3 2023. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • Inclusive Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • Inclusive Capital Partners sold 60,000 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $21.5M.
  • Inclusive Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q3 2023 and held it in 1 quarter.
  • Inclusive Capital Partners's Bio-Rad Laboratories Class A position peaked at $21.5M in Q3 2023.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Inclusive Capital Partners's 13F filing for Q4 2023, filed 12 Feb 2024.